Efficacy of Cold-FX (CVT-E002) in the Prevention of Upper Respiratory Tract Infections in Healthy Adults

• Status: Completed
• Trial end date: 2006-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the Study is to determine the prophylactic effects of CVT-E002 treatment for upper respiratory tract infections in healthy adult employees working with residents in continuing care facilities. It is hypothesized that the use of CVT-E002 will effectively reduce the incidence, severity and duration of upper respiratory infections among the participants when compared to placebo.

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: CV Technologies
• Collaborator: Capital Health, Canada

Criteria

Inclusion Criteria:

• age 18-64 years

• not pregnant or breast feeding

• good general health

Exclusion Criteria:

• medical conditions: HIV infection; malignancy; cardiovascular disease; hypertension; renal, pulmonary or hepatic abnormalities; neurologic or psychiatric disease; tuberculosis; multiple sclerosis; recent acute respiratory infection (<2 weeks)

• medications: warfarin; immunosuppressive therapy; corticosteroids; phenalzine; pentobarbital; haloperidol

• major surgical procedure in the previous six months

• history of alcohol/drug abuse

• pregnancy and lactation in women